Effective Outcome of HBOT as an Adjuvant Therapy in Patients Diagnosed with COVID-19 in a Tertiary Care Hospital – A Preliminary Study

Thiruppathy Palaniappan, Asif Shaikh*, Navamani Kirthika
Medway Hospital, Chennai, India

ABSTRACT

Introduction: Hyperbaricoxygen therapy (HBOT) is breathing 100% oxygen in pressurised chamber. This therapy ensures quick oxygen delivery to the bloodstream. In patients with severe COVID-19 pneumonia, progressive hypoxemia occurs. Oxygen therapy has a significant role in its management. Aim of the study: The objective was to study the efficacy of hyperbaric oxygen therapy (HBOT) as adjuvant therapy for reducing the requirement of additional oxygen supplementation in patients with moderate to severe ARDS diagnosed with COVID-19. Methods: A single-centre prospective pilot cohort study was conducted at a tertiary care hospital from December 2020 to February 2021 over two months. Fifty patients with COVID-19 needing oxygen, satisfying the selection criteria, were included. Hyperbaricoxygen therapy was given to all patients. The patient received 30-45 minutes of hyperbaric oxygen with 15 minutes of pressurizing and depressurizing at 2.0 atmosphere absolute (ATA) with or without airbrakes as per the critical care team. Oxygen requirement, PaO2, and condition at discharge were considered as primary outcome variables. Results: Among the 50 participants studied, the mean age was 53.64±13.26 years. Out of 50 participants, 49(98.00%) had PaO2≤80 mmHg, and one (2.00%) had >80 PaO2. All the participants 50(100%) had PaO2 as 90 mmHg after three sittings. Conclusion: This study shows promising results in using HBOT to overcome respiratory failure in COVID-19. HBOT reduced the need for oxygen by improving the oxygen saturation levels.

Keywords: COVID-19, hyperbaric oxygen therapy, infectious diseases, partial pressure, oxygen

Received: 23 August 2021 / Accepted: 23 April 2022

INTRODUCTION

COVID-19 is the newest member of the betacoronavirus family, first identified in Wuhan province, China, in 2019. Severe acute respiratory syndrome coronavirus two (SARS CoV 2) was named severe acute respiratory syndrome two because of its similarities with the previous viruses [1].

COVID-19 is the second form of SARS, which previously caused a global pandemic to spread almost to 29 countries in 2002. The severity spectrum was classified into mild (81%), severe (14%), or critical (5%) [2], where respiratory failure is the primary cause of death due to SARS virus [3]. Similarly, COVID-19 also affects the respiratory system and causes oxygen deprivation. The abnormal response of host’s immune system leads to a prolonged inflammatory response which causes cytokine storm. In recent times, few cases had no symptoms of pneumonia, but the patient rapidly progressed and fell critically ill with respiratory failure. This can be caused due to alveolocapillary membrane disorder leading to oxygen delivery impairment causing hypoxia. This has been termed as silent or happy hypoxia [4].

Attention should be given to this condition because this leads to oxygen deprivation and leading to drop in partial pressure of oxygen. These patients need immediate oxygen therapy. Standard therapy of oxygen delivery for COVID-19 patients is complex due to the inflammation in the lungs caused by the virus, thereby limiting the oxygen uptake by the red blood cells. Due to this difficulty, hyperbaric oxygen therapy (HBOT) plays an adjuvant role in patients with silent hypoxia by its ability to rapidly increase dissolved oxygen levels in blood and pay the oxygen debt. Within the chamber,
the high-pressure oxygen is delivered through face masks and hoods. The pressure inside the chamber is usually about 250-280 kPa. The HBOT sessions need can be up to five and the duration varies from 45 to 300 min. Vigilant monitoring is essential during HBOT, and amenities for resuscitation, mechanical ventilation must be kept ready [5]. The potential risks and risk-benefit ratio of hyperbaric oxygen have often been underemphasized in therapeutic trials. In routine practise, HBOT is considered safe when the pressure if less than 300 kPa and duration is less than 120 minutes.

This is the first of its kind study done on the role of HBOT in COVID-19 patients. This paper focuses on the effect of HBOT in reducing the requirement of additional oxygen supplementation in moderate and severe COVID-19 patients admitted at a tertiary care hospital.

## Methods

A prospective pilot cohort study has conducted at a tertiary care hospital, from December 2020 to February 2021 over two months. The patients signed informed written consents. The critical care team selected fifty COVID-19 patients based on the selection criteria by convenient sampling technique. Patients included in the current study were those patients above 18 years of age and less than 85 years, who were within seven days of developing oxygen demand, positive SARS-CoV-2 RT-PCR, rapid antigen positive with HRCT score more than 20/40 CORADS, those with respiratory insufficiency in room air i.e., SpO2 <90% or PaO2/FiO2<300mmHg in room air with PaO2 based on arterial blood gas analysis of less than 80, patients requiring oxygen more than six liters/min, patients with one or more comorbidities like uncontrolled diabetes, hypertension, Coronary artery disease (CAD), obesity, hypothyroidism, Chronic kidney disease (CKD), chronic liver disease and patients with moderate or severe covid pneumonia. Patients with mild pneumonia and patients with HBOT contraindications such as claustrophobia, pneumothorax, pneumo-mediastinum, an-dear/sinus disease were not allowed in HBOT, known cases of the chronic pulmonary disease: severe emphysema or known case of pulmonary bullae, pregnancy, age above 85 years and patients on mechanical ventilation were excluded from the study.

Patients were screened for COVID-19 with help of rapid antigen test, RT-PCR and HRCT thorax. Were admitted in COVID-19 specialty unit. All patients were treated according to their oxygen requirement and the lung involvement in HRCT thorax.

### Clinical criteria for giving oxygen therapy

1. Patient's SpO2 less than 90% in room air
2. Breathlessness of class 3 as per NYHA.

### Clinical Criteria for starting antiviral therapy and steroid therapy

#### Anti-viral therapy: Inj Remedesvir (Cipla, India) 100mg*2 vials as initial dose considering the patients renal profile (serum creatinine level), followed by 100mg once a day for 4 days and renal profile monitored every alternate day)

1. Patients aged more than 60yrs
2. Patients with comorbidities mentioned in inclusion criteria
3. Patients with CORADS score of more than 20 as per radiological evidence

#### Criteria for steroid therapy

1. Patients with NYHA class 3 breathlessness
2. Oxygen requirement more than 2 liters/min
3. Patients with comorbidities
4. Patients with high blood sugar levels were monitored while giving steroid therapy and treated accordingly with OHA or insulin.

Inflammatory markers checked for the patients were interleukin-6 (IL6), Lactate dehydrogenase (LDH), D dimer, C reactive protein (CRP), Serum ferritin and other markers such as tumor necrosis factor (TNF - alfa), interleukin (IL-8, IL-9). These markers were checked at regular intervals and patients with increased inflammatory markers were managed as per the protocol.

Cytokine storm was considered when patients had symptoms worsening rapidly even after treatment where inflammatory marker were severely deranged specifically CRP markedly elevated. It suggests, patient is progressing to severe form of illness which will involve multi organ damage.

### Criteria for HBOT

Patients with CORADS more than 20 requiring oxygenation showing progressive illness despite of conventional therapy which is antiviral and steroid therapy. And showing signs of increased inflammatory mark-
Patients with comorbidities mentioned above and showing increasing inflammatory markers and rapidly progressing towards multiorgan dysfunction were selected for HBOT.

The study-selected participants were shifted to the COVID-19 unit and were assessed by the critical care team. The patients were taken to the hyperbaric unit by maintaining airborne precautions based on hospital protocol. All team members handling the patients wore complete personal protective equipment. Once the patient was placed inside the monoplane chamber, and the doors were locked, the patient was instructed to remove the PPE and masks.

The patient received 30 to 45 minutes of hyperbaric oxygen with 15 minutes of pressuring and depressurizing at 2.0 ATA with or without airbrakes per the hyperbaric physician. Electrocardiogram (ECG), pulse-oximetry, and temperature monitoring were done at regular intervals inside the hyperbaric chamber. Non-invasive blood pressure monitoring (NIBP) was used safely inside the chambers.

HBOT was given in three sittings on alternate days. The need for oxygen was assessed at the baseline and compared with the need after three sittings of HBOT. PaO2 monitoring was done by ABG (arterial blood gas) monitoring 12th hourly to monitor the further requirement of HBOT, and to note the significance of the treatment by observing the improvement in PaO2 levels; inflammatory markers were checked regularly to observe changes and response to treatment, daily chest x-rays were taken, monitoring of parameters like oxygen requirement, vitals monitoring.

Statistical analysis

Oxygen requirement, PaO2, and condition at discharge were considered as the primary outcome variable. Descriptive statistics was done as per the study objectives. Mean, 95% confidence interval (CI, lower and upper bounds), median, minimum and maximum, and percentage, were used to express the data. Categorical outcomes were compared between study groups using the McNemar test. Data was analyzed by using the coGuide software, V.1.03[6].

Results

A total of 50 subjects were included in the final analysis. The mean age was 53.64±13.26 years in the study population (ranged 29 to 82). Among the study population, 30(60%) participants were male, and the remaining 20(40%) were female. The mean C-reactive protein levels were 62.98 ± 23.12 mg/l, ranged from 56.41 to 69.55, the mean D dimer was 0.53 ± 0.1ng/ml, ranged from 0.50 to 0.56, the mean IL6 was 13.06 ± 9.07 pg/ml, ranged from 10.48 to 15.64. Ferritin was normal for 48(96%) participants and all of them had normal lactate dehydrogenase and the mean CORAD score was 5.18 ± 0.56, ranged from 5.02 to 5.34. There were 4(8%) only with CORAD score 4 and CORAD score 5 and 6 reported in 66%, 26% respectively. (Table 1). Clinical presentation of the patients were fever, cough, which developed over period of 3 days and few had myalgia, vomiting and diarrhea.

The majority of 70% had diabetic mellitus, followed by 60% had hypertension, 88% had moderate severity. The mean ATA depth was 1.7±0.11 in the study population (ranged 1.50 to 1.80). Among Tx time, 29(58.00%) were 45 min. All of them, 50(100%), were in room air condition at discharge. All of them 100% were reported pressure time and de-pressure as 15 min each respectively. Three sittings were considered for all the study participants. (Table 2)

On day 1, for the majority of 36% of participants, we gave 15 liters of oxygen, followed by 26% participants with 13 liters of oxygen and 16% participants with 10 liters of oxygen. The majority of 90% participants showed improvement to room air condition after three sittings of HBOT. Out of 50 participants at admission, 17(34%) had PaO2 ≤60 mmHg, 29(58%) had 61-70 mmHg, 3(6%) had 71-80 mmHg PaO2 and one (2.00%) had >80 mmHg PaO2. All the participants 50(100%) had PaO2 as 90 mmHg after 3 sittings of HBOT. (Table 3)

Those study participants with oxygen requirement of 4 to 10 liters per minute on day one, all 100% reported room air condition after three sittings. Out of 18 participants with 15 liters of oxygen requirement at day one, two (11.11%) reported 4 liters, and one (5.56%) reported 2 liters of oxygen after three sittings. Among three participants at day one with HFNC, one (33.33%) reported 2 liters, 6 liters, and room air condition after three sittings. (Table 4)

Discussion

This study’s significant findings showed improvement in the partial pressure of oxygen after HBOT (PaO2 was reported as 90 mmHg after three sittings irrespective of the PaO2 at day one). The need for oxygen also gradually reduced after the HBOT sittings.
The prominent feature from COVID-19 patients is hypoxia due to respiratory failure. However, recently, some reports showed that COVID-19 patients were admitted to the hospital with low oxygen saturation but without initial symptoms of dyspnoea. Guan reported that dyspnoea was only found in 18.7% of 1099 patients COVID-19 who were hospitalized, despite ratio PaO2/FiO2, abnormal CT scans (86%), and use of supplemental oxygen (41%) [7]. Dr. Richard Levitan found the same result from Bellevue Hospital New York, who observed the blood oxygen levels of COVID-19 patients where they experienced arterial hypoxemia but

| Parameter                     | Summary                              |
|-------------------------------|--------------------------------------|
| Age (in years)                | 53.64 ± 13.26 (ranged 29 to 82)      |
| Gender                        |                                      |
| Male                          | 30 (60.00%)                          |
| Female                        | 20 (40.00%)                          |
| C-reactive protein levels (in mg/L) | 62.98 ± 23.12 (ranged 56.41 to 69.55) |
| D Dimer (in ng/mL)            | 0.53 ± 0.1 (ranged 0.50 to 0.56)     |
| IL-6 (in pg/mL)               | 13.06 ± 9.07 (ranged 10.48 to 15.64) |
| Ferritin (normal) (in ng/mL)  | 48 (96%)                             |
| Lactate dehydrogenase (normal) (in U/L) | 50 (100%)                         |
| CORAD Score                   | 5.18 ± 0.56 (ranged 5.02 to 5.34)    |

| CORAD Score                   |                                      |
| 4 (High- abnormalities suspicious of COVID) | 4 (8%)                      |
| 5 (very high- Typical COVID)   | 33 (66%)                           |

| Parameter                     | Summary                              |
| Comorbidities                 |                                      |
| Diabetic mellitus             | 35 (70%)                             |
| Hypertension                  | 30 (60%)                             |
| Obesity                       | 2 (4%)                               |
| Asthma                        | 1 (2%)                               |
| Dyslipidaemia                 | 1 (2%)                               |
| Hypothyroidism                | 1 (2%)                               |
| Severity of pneumonia         |                                      |
| Moderate                      | 44 (88.00%)                          |
| Severe                        | 6 (12.00%)                           |
| ATA Depth                     | 1.7 ± 0.11 (ranged 1.50 to 1.80)     |
| Tx Time (Minutes)             |                                      |
| 45                            | 29 (58.00%)                          |
| 60                            | 21 (42.00%)                          |
| Condition at discharge        |                                      |
| Breathing room air            | 50 (100%)                            |

Table 2. Summary of clinical and outcome parameter (N=50)

The prominent feature from COVID-19 patients is hypoxia due to respiratory failure. However, recently, some reports showed that COVID-19 patients were admitted to the hospital with low oxygen saturation but without initial symptoms of dyspnoea. Guan reported that dyspnoea was only found in 18.7% of 1099 patients COVID-19 who were hospitalized, despite ratio PaO2/FiO2, abnormal CT scans (86%), and use of supplemental oxygen (41%) [7]. Dr. Richard Levitan found the same result from Bellevue Hospital New York, who observed the blood oxygen levels of COVID-19 patients where they experienced arterial hypoxemia but
did not show equivalent respiratory distress and did not even complain of dyspnea [8,9].

The current study findings show that the oxygen requirement of the patients was reduced once they were put on HBOT. Similar results have been reported worldwide. Two articles that have been published in China show that HBOT has the potential to be used in COVID-19 patients with pneumonia. The first publication was a case report of a patient with very severe symptoms who experienced respiratory failure (not intubated), and the symptoms improved after eight sittings of HBOT at 200 kPa for 95 minutes [10]. Second publication was a report of a patient on the ventilator with more severe disease symptoms with ARDS, who was saved by using HBOT. Four other COVID-19 patients had severe symptoms with ground-glass opacities who could no longer be treated using standard oxygen masks, were treated with 3-5 sittings of HBOT and returned home [11] agent used for sedation, presence of a chest tube, need for vasopressor agents and tolerance and appearance of side effects. Finally, we compared the outcomes of patients according to the presence or absence of acute respiratory distress syndrome (ARDS). The same researchers also performed HBOT therapy on 20 other patients with milder symptoms and had the same successful outcome. Five patients who were not intubated had used oxygen for several days or even weeks with their pre-HBOT oxygen saturation of 70% (using oxygen mask). With daily HBOT administration, the patient experienced a persistent increase in oxygen saturation and improved symptoms the day after. With only 3-8 times HBOT, the patient can go through the hypoxic crisis phase of the disease and be discharged from the hospital. Researchers suggest that giving HBOT at the initial process of the disease can prevent worsening conditions, leading to significant morbidity and mortality of COVID-19 infection [10].

All airborne precautions control was followed in the current study, and all personnel used PPE to reduce cross-infection. Similarly, decreasing rates of cross-sections were observed in the study by Harch P et al. [10]. This makes HBOT an appropriate management modality, reducing the risk of transmission to healthcare workers in the hospital setting.

Thibodeaux et al. [12] reported giving HBOT in 5 patients from April 13th to 20th with symptoms of tachypnoea and low oxygen saturation. The patient was given a high FiO2, and the administration of HBOT is to avoid the use of mechanical ventilation. The therapy given was 2 ATA for 90 minutes nonstop in a monoplace chamber. Treatment was given 1-6 times. The result obtained was all patients were not on a ventilator, and there was a rapid improvement in tachypnoea and an increase in oxygen saturation. Within less than one week from the last therapy, three patients were discharged, and two were still being treated in a stable condition.

Similar to these reports, the current study showed that three sittings of HBOT for 30-45 minutes improved the patient’s oxygen levels (PaO2 was 90 mmHg after three sittings irrespective of the PaO2 at day one) and reduced the need for oxygen.

The limitation of the current study is its small sample size, and long-term follow-ups were not done. Studies involving large sample with the different patient profile is recommended in future.

Until now, COVID-19 has not been included in the list of indications for the use of HBOT. This is the right time to consider including COVID-19 as an indication for HBOT.

### Conclusion

Anti-inflammatory properties, high-pressure ambient and the use of 100% oxygen guarantee through
HBOT, increased oxygen partial pressure in circulation and tissue despite decreased aerated pulmonary in COVID-19 patient with ARDS. With oxygen debt being 'payed' by HBOT, it will reverse tissue hypoxia. Hence, in clinical practice, HBOT can be considered in moderate and severe COVID-19 patients within seven days of developing oxygen demand.

**List of Abbreviations**

Hyperbaric Oxygen Therapy (HBOT)
Atmosphere Absolute (ATA)
High Resolution Computed Tomography (HRCT)
Coronary Artery Disease (CAD)
Chronic Kidney Disease (CKD)
Reverse Transcriptase – Polymerase Chain Reaction (RTPCR)
Non-Invasive Blood Pressure Monitoring (NIBP)
Confidence Interval (CI)
Interleukin-6 (IL-6)
Lactate Dehydrogenase (LDH)
C Reactive Protein (CRP),
Tumour Necrosis Factor (TNF) Alpha

**Conflict of Interest**

None to declare.

**References**

1. Harapan H, Itoh N, Yufika A et al. Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 2020;13(5):667-673. doi:10.1016/j.jiph.2020.03.019

2. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA - J Am Med Assoc. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648

3. Weiss SR, Navas-Martín S. Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus. Microbiol Mol Biol Rev. 2005;69(4):635-664. doi:10.1128/mmbr.69.4.635-664.2005

4. Anisenkova AY, Volozhanin DA, Golota AS, et al. Cytokine storm in covid-19 (scientific review). Prev Clin Med. 2021;(1):89-95. doi:10.47843/2074-9120_2021_1_89

5. Gill AL, Bell CNA. Hyperbaric oxygen: Its uses, mechanisms of action and outcomes. QJM - Mon J Assoc Physicians. 2004;97(7):385-395. doi:10.1093/qjmed/hch074

6. BDSS Corp. Released 2020. coGuide Statistics software, Version 1.0, India: BDSS corp. Available from: https://www.coguide.in. [Last accessed on 2021 Dec 22].

7. Guan W, Ni Z, Med YH-NEJ. Clinical characteristics of coronavirus disease 2019 in China. 2020. N Engl J Med. 2020;382(18):1708-1720.

8. Allali G, Marti C, Grosgeurin O, Morélot-Panzini C, Similowski T, Adler D. Dyspnea: The vanished warning symptom of COVID-19 pneumonia. J Med Virol. 2020;92(11):2272-2273. doi:10.1002/jmv.26172

9. Jennifer Couzin-Frankel. The mystery of the pandemic’s happy hypoxia. Science. 2020;368(6490):455-456.

10. Harch P. Hyperbaric oxygen treatment of novel coronavirus (COVID-19) respiratory failure. Med Gas Res. 2020;10(2):61-62. doi:10.4103/2045-9912.282177

11. Bessereau J, Aboab J, Hullin T, et al. Safety of hyperbaric oxygen therapy in mechanically ventilated patients. Int Marit Health. 2017;68(1):46-51. doi:10.5603/IMH.2017.0008

12. Thibodeaux K, Speyrer M, Raza A, Yaakov R, Serena TE. Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series. J Wound Care. 2020;29(Sup5a):S4-S8. doi:10.12968/jowc.2020.29.Sup5a.S4